Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

Performance of NOVO-B Novo Nordisk A/S | 22.7% in 12m

Compare NOVO-B with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?

Compare Novo Nordisk A/S with its related Sector/Index XBI

Compare Novo Nordisk A/S with its related Sector/Index XBI

Performance Duell NOVO-B vs XBI

TimeFrame NOVO-B XBI
1 Week -6.22% -0.93%
1 Month -15.6% -1.01%
3 Months -18.8% 6.34%
6 Months -10.6% 9.11%
12 Months 22.7% 36.28%
YTD 13.6% 8.22%
Rel. Perf. 1m -1.33
Rel. Perf. 3m -2.00
Rel. Perf. 6m -1.65
Rel. Perf. 12m -1.65
Spearman 1m -0.83 -0.25
Spearman 3m -0.50 0.12

Is Novo Nordisk A/S a good stock to buy?

Neither. Based on ValueRay Fundamental Analyses, Novo Nordisk A/S is currently (October 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 30.43 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NOVO-B as of October 2024 is 1048.75. This means that NOVO-B is currently undervalued and has a potential upside of +34.77% (Margin of Safety).

Is NOVO-B a buy, sell or hold?

Novo Nordisk A/S has no consensus analysts rating. ValueRay therefore judges the recommendation based on the last 12 Month Returns of 22.67%.

In compare to SPDR S&P Biotech, NOVO-B made -13.61% less over the last 12 months. Due to the underperformance, it is recommend to sell NOVO-B.
Values above 0%: NOVO-B is performing better - Values below 0%: NOVO-B is underperforming

Compare NOVO-B with Broad Market Indices

Symbol 1w 1m 6m 12m
US S&P 500 SPY -6.48% -19.90% -22.95% -11.67%
US NASDAQ 100 QQQ -6.34% -21.53% -22.85% -11.19%
US Dow Jones Industrial 30 DIA -6.33% -19.05% -21.19% -5.58%
German DAX 40 DBXD -4.40% -18.47% -14.04% -2.69%
UK FTSE 100 ISFU -3.50% -15.54% -19.99% 2.94%
Shanghai Shenzhen CSI 300 CSI 300 -26.31% -58.09% -44.47% -7.70%
Hongkong Hang Seng HSI -13.16% -42.11% -42.33% 1.18%
Japan Nikkei 225 EXX7 -7.47% -20.45% -10.06% 4.02%
India NIFTY 50 INDA -2.79% -14.80% -21.29% -6.84%
Brasil Bovespa EWZ -5.14% -15.01% -5.24% 17.07%

NOVO-B Novo Nordisk A/S vs. Sectors

Symbol 1w 1m 6m 12m
Communication Services XLC -7.19% -22.43% -22.45% -13.17%
Consumer Discretionary XLY -4.89% -22.90% -22.47% -1.60%
Consumer Staples XLP -4.35% -13.69% -21.77% -2.85%
Energy XLE -13.09% -22.61% -8.16% 13.87%
Financial XLF -7.33% -16.38% -22.27% -17.67%
Health Care XLV -5.32% -12.76% -18.21% 4.60%
Industrial XLI -6.72% -21.23% -20.63% -11.75%
Materials XLB -4.41% -19.76% -15.04% -1.64%
Real Estate XLRE -4.48% -15.75% -26.68% -9.82%
Technology XLK -6.30% -23.22% -21.34% -11.56%
Utilities XLU -7.33% -22.13% -37.58% -22.59%
Aerospace & Defense XAR -7.86% -20.55% -27.15% -16.19%
Biotech XBI -5.29% -14.57% -19.68% -13.61%
Homebuilder XHB -3.86% -23.10% -24.16% -38.55%
Retail XRT -4.90% -19.38% -14.45% -8.84%

NOVO-B Novo Nordisk A/S vs. Commodities

Symbol 1w 1m 6m 12m
Oil USO -14.87% -25.26% -3.37% 23.68%
Natural Gas UNG -3.59% -34.00% -17.55% 72.10%
Gold GLD -6.21% -21.90% -26.40% -19.10%
Silver SLV -7.95% -29.91% -30.46% -23.69%
Copper CPER -6.05% -27.92% -19.44% -3.44%

Returns of NOVO-B vs. Yields & Bonds

Symbol 1w 1m 6m 12m
iShares 20+ Years Bond TLT -3.47% -12.40% -15.73% 8.14%
iShares High Yield Corp. Bond HYG -5.76% -16.87% -17.78% 6.60%
Does Novo Nordisk A/S outperform its market, is NOVO-B a Sector Leader?
No, over the last 12 months Novo Nordisk A/S (NOVO-B) made 22.67%, while its related Sector, the SPDR S&P Biotech (XBI) made 36.28%.
Over the last 3 months NOVO-B made -18.77%, while XBI made 6.34%.
Period NOVO-B XBI S&P 500
1 Month -15.58% -1.01% 4.32%
3 Months -18.77% 6.34% 3.62%
12 Months 22.67% 36.28% 34.34%